QQQ   294.43 (-0.06%)
AAPL   143.07 (-0.85%)
MSFT   247.22 (-0.24%)
META   147.61 (-0.91%)
GOOGL   98.39 (-0.46%)
AMZN   102.39 (-0.72%)
TSLA   173.80 (+0.33%)
NVDA   199.87 (+2.30%)
NIO   12.31 (+1.99%)
BABA   112.80 (+2.36%)
AMD   79.66 (+6.00%)
T   20.42 (+0.25%)
MU   61.08 (+1.29%)
F   13.65 (+1.04%)
CGC   3.04 (+0.33%)
GE   81.17 (+0.86%)
DIS   108.54 (+0.05%)
AMC   5.57 (+4.11%)
PFE   43.81 (-0.79%)
PYPL   81.13 (-0.44%)
NFLX   352.39 (-0.42%)
QQQ   294.43 (-0.06%)
AAPL   143.07 (-0.85%)
MSFT   247.22 (-0.24%)
META   147.61 (-0.91%)
GOOGL   98.39 (-0.46%)
AMZN   102.39 (-0.72%)
TSLA   173.80 (+0.33%)
NVDA   199.87 (+2.30%)
NIO   12.31 (+1.99%)
BABA   112.80 (+2.36%)
AMD   79.66 (+6.00%)
T   20.42 (+0.25%)
MU   61.08 (+1.29%)
F   13.65 (+1.04%)
CGC   3.04 (+0.33%)
GE   81.17 (+0.86%)
DIS   108.54 (+0.05%)
AMC   5.57 (+4.11%)
PFE   43.81 (-0.79%)
PYPL   81.13 (-0.44%)
NFLX   352.39 (-0.42%)
QQQ   294.43 (-0.06%)
AAPL   143.07 (-0.85%)
MSFT   247.22 (-0.24%)
META   147.61 (-0.91%)
GOOGL   98.39 (-0.46%)
AMZN   102.39 (-0.72%)
TSLA   173.80 (+0.33%)
NVDA   199.87 (+2.30%)
NIO   12.31 (+1.99%)
BABA   112.80 (+2.36%)
AMD   79.66 (+6.00%)
T   20.42 (+0.25%)
MU   61.08 (+1.29%)
F   13.65 (+1.04%)
CGC   3.04 (+0.33%)
GE   81.17 (+0.86%)
DIS   108.54 (+0.05%)
AMC   5.57 (+4.11%)
PFE   43.81 (-0.79%)
PYPL   81.13 (-0.44%)
NFLX   352.39 (-0.42%)
QQQ   294.43 (-0.06%)
AAPL   143.07 (-0.85%)
MSFT   247.22 (-0.24%)
META   147.61 (-0.91%)
GOOGL   98.39 (-0.46%)
AMZN   102.39 (-0.72%)
TSLA   173.80 (+0.33%)
NVDA   199.87 (+2.30%)
NIO   12.31 (+1.99%)
BABA   112.80 (+2.36%)
AMD   79.66 (+6.00%)
T   20.42 (+0.25%)
MU   61.08 (+1.29%)
F   13.65 (+1.04%)
CGC   3.04 (+0.33%)
GE   81.17 (+0.86%)
DIS   108.54 (+0.05%)
AMC   5.57 (+4.11%)
PFE   43.81 (-0.79%)
PYPL   81.13 (-0.44%)
NFLX   352.39 (-0.42%)
NYSE:TAK

Takeda Pharmaceutical - TAK Stock Forecast, Price & News

$15.78
-0.02 (-0.13%)
(As of 02/1/2023 09:47 AM ET)
Add
Compare
Today's Range
$15.67
▼
$15.79
50-Day Range
$14.36
▼
$16.27
52-Week Range
$12.28
▼
$16.30
Volume
164,174 shs
Average Volume
3.17 million shs
Market Capitalization
$48.93 billion
P/E Ratio
29.22
Dividend Yield
3.40%
Price Target
$24.00

Takeda Pharmaceutical MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
51.9% Upside
$24.00 Price Target
Short Interest
Healthy
0.28% of Float Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
0.49mentions of Takeda Pharmaceutical in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.23 out of 5 stars

Medical Sector

385th out of 1,053 stocks

Pharmaceutical Preparations Industry

189th out of 519 stocks

See Top Rated MarketRank™ Stocks Here

TAK stock logo

About Takeda Pharmaceutical (NYSE:TAK) Stock

Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.

Receive TAK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Takeda Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

TAK Stock News Headlines

February 1, 2023 | finance.yahoo.com
Finch Therapeutics Halts Work On Its Only Clinical Stage Asset, Cuts 95% Of Workforce
January 31, 2023 | marketwatch.com
Metabolism Drugs Market [2023-2029] Upcoming Scenario, Key Perspectives, and Top Companies: Merck, Novartis, Takeda Pharmaceutical, Astra Zeneca
February 1, 2023 | PressReach (Ad)
Top Lithium Stock To Watch
Today's stock market news features a lithium stock with blue sky potential.
January 24, 2023 | americanbankingnews.com
Head to Head Survey: Takeda Pharmaceutical (NYSE:TAK) & ADC Therapeutics (NYSE:ADCT)
January 23, 2023 | msn.com
Li Ka-shing’s HutchMed strikes US$1.1 billion deal with unit of Japan’s Takeda to license colon cancer drug
January 23, 2023 | proactiveinvestors.com
Hutchmed shares jump on US$1.13bn Takeda deal
January 23, 2023 | finance.yahoo.com
Takeda To Acquire Exclusive Worldwide (ex-China) License of HUTCHMED’s Fruquintinib, a Highly Selective, Oral VEGFR1/2/3 Tyrosine Kinase Inhibitor
January 23, 2023 | finance.yahoo.com
HUTCHMED Announces License to Takeda to Develop and Commercialize Fruquintinib Outside China
February 1, 2023 | PressReach (Ad)
Top Innovation Stock
Today's stock market report features an AI Robotics tech stock with a $4 million order backlog.
January 23, 2023 | finance.yahoo.com
Takeda inks deal with Hutchmed for up to $1.1 billion
January 23, 2023 | marketwatch.com
Diabetes Drugs Market 2023 Size, Share, Trend and Forecast to 2028
January 20, 2023 | marketwatch.com
Insomnia Therapeutics Drugs Market Research on Present State and Future Growth Prospects of Key Players, Forecast by 2023 To 2028
January 20, 2023 | msn.com
Bio-pharmaceutical company Takeda appoints new country manager for its operations in Romania
January 20, 2023 | msn.com
Indonesian Minister Explores Investment plan with Takeda for Dengue Fever Vaccine
January 19, 2023 | marketwatch.com
Metabolic Disease Treatment Market Size, Latest Trends, Share, Top Players, Revenue and Forecast 2029
January 18, 2023 | finance.yahoo.com
Drop in China-bound Japanese exports adds to fears of global downturn
January 17, 2023 | finance.yahoo.com
Takeda Recognized as a Top Employer in Canada in 2023
January 16, 2023 | finance.yahoo.com
Takeda Named Global Top Employer for Sixth Consecutive Year
January 16, 2023 | marketwatch.com
Marine Pharmaceuticals Market Major Segments, Size Parameters and Topmost Key Players - Seattle Genetics, DSM, Eisai Co, Takeda
January 16, 2023 | marketwatch.com
Hemorrhoid Treatment Market 2023 : Trends, Industry Structure, Development, Demographics, Developing Factors By 2029
January 13, 2023 | marketwatch.com
Colchicine Market Is Booming With Great Opportunities and Growing With Top Key players
January 12, 2023 | marketwatch.com
Anti-spasmodic Drugs Market Detailed Analysis of Current Scenario with Growth Forecasts to 2028
January 12, 2023 | msn.com
Former Takeda worker and boyfriend accused of defrauding drug firm of more than $2.3 million
January 12, 2023 | marketwatch.com
Lipid Metabolism Disease Market: Size |Incredible Possibilities and Growth Analysis and Forecast to 2028 | Newst 95 Pages Report
January 12, 2023 | marketwatch.com
Antacid Market Regional Assessment and Competitive Landscape:AstraZeneca, Takeda Pharmaceutical, Pfizer, Reckitt Benckiser
January 11, 2023 | marketwatch.com
Antidiabetics Market Players to drive Merges and Acquisition Strategies to Expand Market Share, 2023-2025
January 11, 2023 | markets.businessinsider.com
Takeda'S Exkivity Gets Approval In China For Metastatic Lung Cancer After Chemo
See More Headlines
Receive TAK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Takeda Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

TAK Company Calendar

Today
2/01/2023
Next Earnings (Estimated)
2/02/2023
Fiscal Year End
3/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSE:TAK
CUSIP
N/A
CIK
1395064
Web
www.takeda.com
Phone
(166) 204-2111
Fax
813-3278-2268
Employees
47,347
Year Founded
1781

Price Target and Rating

Average Stock Price Forecast
$24.00
High Stock Price Forecast
$24.00
Low Stock Price Forecast
$24.00
Forecasted Upside/Downside
+52.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$0.54
Trailing P/E Ratio
29.22
Forward P/E Ratio
7.51
P/E Growth
N/A
Net Income
$2.05 billion
Net Margins
5.60%
Pretax Margin
5.86%
Return on Equity
12.76%
Return on Assets
5.61%

Debt

Debt-to-Equity Ratio
0.62
Current Ratio
1.15
Quick Ratio
0.75

Sales & Book Value

Annual Sales
$31.79 billion
Price / Sales
1.54
Cash Flow
$3.55 per share
Price / Cash Flow
4.44
Book Value
$16.31 per share
Price / Book
0.97

Miscellaneous

Outstanding Shares
3,100,720,000
Free Float
3,099,482,000
Market Cap
$48.93 billion
Optionable
Optionable
Beta
0.65

Social Links


Key Executives

  • Mr. Christophe Weber (Age 57)
    Pres, CEO & Representative Director
    Comp: $4.45M
  • Mr. Constantine Saroukos (Age 52)
    CFO & Representative Director
    Comp: $2.66M
  • Dr. Andrew S. Plump (Age 58)
    Pres of R&D and Representative Director
    Comp: $2.53M
  • Dr. Seigo Izumo
    Chair of Management Board
  • Mr. Haruhiko Hirate (Age 66)
    Member of Management Board
  • Salvatore Alesci
    Member of Management Board and Head of R&D Global Science & Biomedical Policy
  • Norimasa Takeda
    Chief Accounting Officer & Corp. Controller
  • Mr. Iwaaki Taniguchi
    Sr. VP of Corp. Fin. & Controlling Department
  • Mr. Gabriele Ricci (Age 45)
    Chief Data & Technology Officer
  • Mr. Christopher David O'Reilly
    Global Head of Investor Relations & Global Fin.

Key Competitors

View All Competitors

Insiders & Institutions

View All Institutional Transactions













TAK Stock - Frequently Asked Questions

Should I buy or sell Takeda Pharmaceutical stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Takeda Pharmaceutical in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" TAK shares.
View TAK analyst ratings or view top-rated stocks.

What is Takeda Pharmaceutical's stock price forecast for 2023?

3 analysts have issued 12 month target prices for Takeda Pharmaceutical's shares. Their TAK share price forecasts range from $24.00 to $24.00. On average, they expect the company's stock price to reach $24.00 in the next twelve months. This suggests a possible upside of 51.9% from the stock's current price.
View analysts price targets for TAK or view top-rated stocks among Wall Street analysts.

How have TAK shares performed in 2023?

Takeda Pharmaceutical's stock was trading at $15.60 at the start of the year. Since then, TAK stock has increased by 1.3% and is now trading at $15.80.
View the best growth stocks for 2023 here.

Are investors shorting Takeda Pharmaceutical?

Takeda Pharmaceutical saw a increase in short interest during the month of January. As of January 15th, there was short interest totaling 8,730,000 shares, an increase of 19.3% from the December 31st total of 7,320,000 shares. Based on an average trading volume of 2,880,000 shares, the days-to-cover ratio is currently 3.0 days. Currently, 0.3% of the company's shares are sold short.
View Takeda Pharmaceutical's Short Interest.

When is Takeda Pharmaceutical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 2nd 2023.
View our TAK earnings forecast.

Is Takeda Pharmaceutical a good dividend stock?

Takeda Pharmaceutical (NYSE:TAK) pays an annual dividend of $0.54 per share and currently has a dividend yield of 3.37%. The dividend payout ratio is 100.00%. Payout ratios above 75% are not desirable because they may not be sustainable.

What guidance has Takeda Pharmaceutical issued on next quarter's earnings?

Takeda Pharmaceutical updated its FY 2022 earnings guidance on Thursday, November, 3rd. The company provided EPS guidance of $3.80-$3.80 for the period. The company issued revenue guidance of $28.46 billion-$28.46 billion.

What other stocks do shareholders of Takeda Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Takeda Pharmaceutical investors own include Cisco Systems (CSCO), Johnson & Johnson (JNJ), Alibaba Group (BABA), Pfizer (PFE), Verizon Communications (VZ), AbbVie (ABBV), CVS Health (CVS), Gilead Sciences (GILD), AT&T (T) and Abbott Laboratories (ABT).

What is Takeda Pharmaceutical's stock symbol?

Takeda Pharmaceutical trades on the New York Stock Exchange (NYSE) under the ticker symbol "TAK."

Who are Takeda Pharmaceutical's major shareholders?

Takeda Pharmaceutical's stock is owned by a variety of institutional and retail investors. Top institutional investors include Natixis Advisors L.P. (0.02%), Clean Yield Group (0.02%), Manning & Napier Group LLC (0.01%), Sippican Capital Advisors (0.00%), Comerica Bank (0.00%) and Vestmark Advisory Solutions Inc. (0.00%).

How do I buy shares of Takeda Pharmaceutical?

Shares of TAK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Takeda Pharmaceutical's stock price today?

One share of TAK stock can currently be purchased for approximately $15.80.

How much money does Takeda Pharmaceutical make?

Takeda Pharmaceutical (NYSE:TAK) has a market capitalization of $48.99 billion and generates $31.79 billion in revenue each year. The company earns $2.05 billion in net income (profit) each year or $0.54 on an earnings per share basis.

How many employees does Takeda Pharmaceutical have?

The company employs 47,347 workers across the globe.

Does Takeda Pharmaceutical have any subsidiaries?
The following companies are subsidiares of Takeda Pharmaceutical: ARIAD Pharmaceuticals, Baxalta Manufacturing S.à r.l., IDM Pharma Inc., Intellikine, Inviragen, LigoCyte Pharmaceuticals, Meritage Pharma Inc., Millennium Pharmaceuticals, Millennium Pharmaceuticals Inc., Nihon Pharmaceutical Co. Ltd., Nycomed Pharma, PvP Biologics, Shire, Shire ViroPharma LLC, Takeda (China) Holdings Co. Ltd., Takeda AS, Takeda Austria GmbH, Takeda Bio Development Center, Takeda California Inc., Takeda Consumer Healthcare Company Limited, Takeda Development Center Americas Inc., Takeda Development Center Asia Pte. Ltd., Takeda Development Centre Europe Ltd., Takeda Distribuidora Ltda., Takeda France S.A.S., Takeda GmbH, Takeda Ireland Limited, Takeda Italia S.p.A., Takeda Pharma A/S, Takeda Pharmaceutical (China) Company Limited, Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals Korea Co. Ltd., Takeda Pharmaceuticals Limited Liability Company, Takeda Pharmaceuticals U.S.A. Inc., Takeda UK Limited, Takeda Vaccines Inc., Takeda Vaccines Pte. Ltd., and TiGenix.
Read More
How can I contact Takeda Pharmaceutical?

Takeda Pharmaceutical's mailing address is 1-1 NIHONBASHI-HONCHO 2-CHOME CHUO-KU, TOKYO M0, 103-8668. The official website for the company is www.takeda.com. The company can be reached via phone at (166) 204-2111 or via fax at 813-3278-2268.

This page (NYSE:TAK) was last updated on 2/1/2023 by MarketBeat.com Staff